1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

Takeda Test Drives EMA’s Parallel Review Route For EU And Non-EU Markets

Company Submits Two Sets Of Applications For Evaluation Of Its Dengue Vaccine To CHMP

 
• By Vibha Sharma

A new evaluation route that the European Medicines Agency launched last year came at the right time for Takeda’s dengue vaccine candidate. 

Dengue - Phrase in History of the Present Illness
Dengue is the most rapidly spreading mosquito-borne disease • Source: Alamy

A dengue vaccine that has been in the making for 15 years will become the first ever product to undergo the European Medicines Agency’s new mechanism that allows for the parallel review of products for use in the EU and non-EU markets.

The product is TAK-003, Takeda’s tetravalent dengue vaccine candidate for the prevention of the mosquito-borne disease in individuals aged 4-60 years. The company has submitted two near-identical applications for evaluation...

Dramatic Rise Of Dengue

Dengue is the most rapidly spreading mosquito-borne disease globally, with over 50 million cases occurring every year. Before 1970, only nine countries had experienced severe dengue...

More from Review Pathways

More from Pathways & Standards

User Fee-Funded Staff Would Drop In FY 2026 US FDA Budget

 
• By Derrick Gingery

The reductions across medical product programs in the agency’s budget request include hundreds of positions funded by user fees, which may foreshadow its upcoming user fee restructuring strategy.

EMA Official Clarifies Benefits And Limitations Of Innovation Pathways

 
• By Eliza Slawther

A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.

Drug, Biologic Policy Staff Return To US FDA, As RIF Process Hangs In Legal Limbo

 
• By Sarah Karlin-Smith

The FDA employees with reduction-in-force notice rescissions include some who work on user fee negotiations, but staff still subject to RIFs will not officially separate from the agency this week due to ongoing legal challenges.